Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$39.04 USD

39.04
2,512,037

-0.12 (-0.31%)

Updated Jul 15, 2024 09:40 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Are Medical Stocks Lagging GSK PLC Sponsored ADR (GSK) This Year?

Here is how GSK (GSK) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.

GSK (GSK) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?

Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Sanofi (SNY), AstraZeneca's RSV Antibody Gets FDA Nod in Infants

Following FDA approval, Sanofi (SNY)/AstraZeneca's (AZN) Beyfortus is the first RSV antibody approved to protect all infants. The companies plan to make it available ahead of the upcoming RSV season.

GSK (GSK) Stock Sinks As Market Gains: What You Should Know

GSK (GSK) closed the most recent trading day at $34.51, moving -0.06% from the previous trading session.

GSK (GSK) Outpaces Stock Market Gains: What You Should Know

GSK (GSK) closed the most recent trading day at $34.80, moving +0.87% from the previous trading session.

Abhinab Dasgupta headshot

3 Healthcare Stocks to Buy Amid Market Volatility

Patterson (PDCO), Perrigo (PRGO) and GSK are three healthcare stocks that can lend solidity to one's portfolio today and provide big returns in the foreseeable future.

Why GSK (GSK) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

GSK (GSK) Dips More Than Broader Markets: What You Should Know

In the latest trading session, GSK (GSK) closed at $33.81, marking a -0.82% move from the previous day.

GSK vs. TECH: Which Stock Is the Better Value Option?

GSK vs. TECH: Which Stock Is the Better Value Option?

Moderna (MRNA) Initiates Rolling BLA Filing for RSV Vaccine

Alongside the FDA filing, Moderna (MRNA) submits similar filings in Europe and Australia, seeking approval for using its RSV vaccine in older adults aged 60 years and above.

Is WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) a Strong ETF Right Now?

Smart Beta ETF report for DNL

GSK (GSK) Stock Sinks As Market Gains: What You Should Know

GSK (GSK) closed at $35.29 in the latest trading session, marking a -0.98% move from the prior day.

GSK's (GSK) Gonorrhoea Vaccine Gets FDA Fast Track Tag

The FDA grants fast-track designation to GSK's investigational gonorrhoeae vaccine candidate. The grant enables GSK to seek expedited review for a potential FDA filing of the vaccine.

GSK (GSK) Stock Moves -0.3%: What You Should Know

GSK (GSK) closed at $36.27 in the latest trading session, marking a -0.3% move from the prior day.

Is GSK PLC Sponsored ADR (GSK) Stock Outpacing Its Medical Peers This Year?

Here is how GSK (GSK) and Ligand Pharmaceuticals (LGND) have performed compared to their sector so far this year.

Company News for Jun 26, 2023

Companies in The News Are: KMX, GS, SBUX, GSK.

Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More

Acquisition and regulatory updates from DICE and GSK plc (GSK ) are in focus in the biotech sector.

GSK (GSK) Dips More Than Broader Markets: What You Should Know

GSK (GSK) closed the most recent trading day at $34.62, moving -1.51% from the previous trading session.

GSK vs. TECH: Which Stock Should Value Investors Buy Now?

GSK vs. TECH: Which Stock Is the Better Value Option?

GSK Announces Extension of FDA Review for Rare Blood Therapy

GSK announces the FDA's extension of the review period of its new drug application for momelotinib to treat myelofibrosis by three months. A decision is now expected on Sep 16, 2023.

GSK (GSK) Outpaces Stock Market Gains: What You Should Know

GSK (GSK) closed at $34.64 in the latest trading session, marking a +0.73% move from the prior day.

FDA Panel Endorses AstraZeneca (AZN), Sanofi's RSV Antibody

The FDA's AMDAC unanimously recommends AstraZeneca (AZN)/Sanofi's (SNY) nirsevimab as full immunization against RSV disease for all infants.

Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More

Regulatory and pipeline updates from GSK plc (GSK) and Biogen (BIIB) are in focus in the biotech sector.

GSK (GSK) Dips More Than Broader Markets: What You Should Know

GSK (GSK) closed the most recent trading day at $34.36, moving -0.75% from the previous trading session.